VERU

VERU INC. (VERU) - 10-K Filing Summary

Business Context and Reporting Period

Company: VERU INC.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2024
Business Overview: Veru is a late clinical-stage biopharmaceutical company focused on developing novel medicines for metabolic diseases, oncology, and viral-induced Acute Respiratory Distress Syndrome (ARDS). Its commercial operations rely on the FC2 Female Condom, an FDA-approved internal condom for pregnancy and STI prevention. The company's primary drug candidates are enobosarm (a selective androgen receptor modulator) and sabizabulin (a microtubule disruptor).

Key Financial Metrics

Revenue Composition: Revenues are derived almost entirely from FC2 sales. In Fiscal 2024, the global public health sector accounted for 86% of revenue ($14.5 million), while the U.S. prescription channel accounted for 14% ($2.4 million). This represents a shift from Fiscal 2023, where the U.S. channel was 36% of revenue.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss decreased significantly from $93.2 million in 2023 to $37.8 million in 2024. This improvement was driven primarily by a reduction in Research and Development (R&D) expenses from $51.2 million to $12.8 million and Selling, General, and Administrative (SG&A) expenses from $48.1 million to $31.2 million.
• Expense Reduction Drivers: The decrease in R&D and SG&A is attributed to the strategic decision to pause or terminate several clinical programs (including sabizabulin for COVID-19 and prostate cancer) and the sale of the ENTADFI asset in April 2023, which eliminated associated commercialization costs.
• Revenue Mix Shift: U.S. prescription revenue declined due to the Chapter 11 bankruptcy of The Pill Club, a major customer in the prior year. Conversely, global public health sector revenue increased due to timing and shipment of large orders (e.g., South Africa and Brazil tenders).
• Liquidity Improvement: Cash on hand increased from $9.6 million to $24.9 million, primarily due to a public offering of common stock in December 2023 that generated approximately $35.2 million in net proceeds.
• Gain on Sale: The company recognized a $1.2 million gain on the sale of ENTADFI assets in 2024, compared to a $5.7 million gain in 2023.

Guidance, Outlook, Risks, and Contingencies

Going Concern Warning: The independent registered public accounting firm has included an explanatory paragraph in its audit report stating that the company's losses from operations and need for additional funding raise substantial doubt about its ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management estimates current cash is insufficient to fund operations for the next 12 months without additional financing.

Capital Raising Constraints: Due to the failure to timely file two reports with the SEC (Q4 2023 10-Q and an 8-K), Veru is ineligible to use its Form S-3 shelf registration statement or file new S-3 statements until March 1, 2025. This significantly impairs the company's ability to raise capital quickly or on favorable terms.

Development Priorities:

• Enobosarm (Obesity): The primary focus. The Phase 2b QUALITY clinical trial (evaluating enobosarm with semaglutide) completed enrollment in August 2024. Topline results are expected in January 2025.
• Enobosarm (Breast Cancer): Development is suspended pending sufficient funding. Stage 1a of the Phase 3 trial was completed in 2023.
• Sabizabulin (ARDS): Development is suspended pending external funding (grants or partnerships). The FDA declined an Emergency Use Authorization (EUA) in February 2023.

Key Risks and Contingencies:

• ONCO Promissory Notes: Veru sold ENTADFI assets to Onconetix, Inc. (ONCO) for $20 million, with significant portions payable via promissory notes. ONCO has defaulted on payments. A Forbearance Agreement is in place, but there is uncertainty regarding the collection of the remaining principal and interest. Veru holds ONCO common stock (converted from preferred stock) valued at approximately $0.7 million.
• Supplier Dispute: Veru resolved a dispute with a supplier regarding sabizabulin commercialization costs by agreeing to pay $8.3 million over time. A portion of this liability is contingent on payments received from ONCO.
• FC2 Supply Chain: The company relies on a single supplier for the nitrile polymer used in FC2. The supplier is closing the specific facility producing Veru's grade, requiring a transition to an alternative grade and FDA approval, which poses supply and cost risks.
• Nasdaq Delisting: Veru received a notice of delisting from Nasdaq due to its stock price falling below $1.00 per share. It has until February 25, 2025, to regain compliance.
• Legal Proceedings: The company is a defendant in multiple shareholder class actions and derivative lawsuits alleging securities violations and breach of fiduciary duty related to sabizabulin disclosures.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline of cash burn and the company's concrete plans to secure financing before the March 1, 2025, S-3 eligibility date.
• ONCO Collectability: Assess the likelihood of collecting the remaining ~$9.5 million in principal and interest from ONCO's promissory notes and the value of the ONCO common stock held.
• Enobosarm Trial Results: Monitor the January 2025 topline data release for the Phase 2b QUALITY trial, which is critical for future funding and valuation.
• FC2 Revenue Stability: Evaluate the sustainability of global public health sector revenue given pricing pressures and the loss of the U.S. Pill Club channel.
• Internal Controls: Confirm the effectiveness of remediated internal controls over financial reporting following the restatements of prior periods.
• Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 threshold for 10 consecutive days before the February 2025 deadline to avoid delisting.